Sunday Program

Simultaneous Sessions | Science in progress | Clinical Trial Update | Hematology-in-focus Session | Plenary Session 2 |

CLINICAL TRIAL UPDATE
08:00 – 09:15, Hall A1

ACUTE LYMPHOBLASTIC LEUKEMIA
Chair: D Hoelzer (University Frankfurt, Frankfurt, Germany)

IMPROVED RISK DEFINITION AND RISK-ORIENTED THERAPY IN SUCCESSIVE NILG STUDIES
R Bassan (Ospedali Riuniti, Bergamo, Italy)

THE PEDIATRIC-INSPIRED GRAALL APPROACH IN PH-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
H Dombret (Hôpital Saint-Louis, Paris, France)

MRD-ORIENTES TREATMENT IN HIGH-RISK ADULT ACUTE LYMPHOBLASTIC LEUKEMIA. INTERIM RESULTS OF PETHEMA LAL AR-03 TRIAL
J Ribera (Hospital Germans Trias i Pujol, Badalona, Spain)

ANTIBODY THERAPY IN THE ONGOING GMALL STUDIES
D Hoelzer (University Frankfurt, Frankfurt, Germany)

PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS: SOME RESULTS FROM MRC UKALL12/ECOG2993
A Fielding (University College Medical School, London, United Kingdom)

THE GIMEMA STRATEGY FOR PH+ ACUTE LYMPHOBLASTIC LEUKEMIA
R Foá (Università "La Sapienza", Rome, Italy)

CLINICAL TRIAL UPDATE
10:30 – 11:45, Hall A1

SPECIFIC B-CELL LYMPHOMA ENTITIES
Chair: M Dreyling (University of München-Großhadern, Munchen, Germany)

CENTRAL NERVOUS SYSTEM LYMPHOMA
A Ferreri (San Raffaele Scientific Institute, Milan, Italy)

MALT LYMPHOMA
E Zucca (Oncology Institute of Southern Switzerland, Bellinzona,
Switzerland)

MANTLE CELL LYMPHOMA
M Dreyling (University of München-Großhadern, Munchen, Germany)